Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Profit After Tax (2020 - 2025)

Vivos Therapeutics' Profit After Tax history spans 6 years, with the latest figure at -$7.0 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$7.0 million for Q4 2025, down 149.16% from a year ago — trailing twelve months through Dec 2025 was -$21.2 million (down 91.55% YoY), and the annual figure for FY2025 was -$21.2 million, down 91.26%.
  • Profit After Tax for Q4 2025 was -$7.0 million at Vivos Therapeutics, down from -$5.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$1.7 million in Q1 2023 to a low of -$7.4 million in Q4 2021.
  • The 5-year median for Profit After Tax is -$4.6 million (2023), against an average of -$4.5 million.
  • The sharpest move saw Profit After Tax crashed 200.74% in 2021, then surged 68.05% in 2023.
  • Year by year, Profit After Tax stood at -$7.4 million in 2021, then grew by 18.23% to -$6.0 million in 2022, then grew by 29.15% to -$4.3 million in 2023, then skyrocketed by 34.84% to -$2.8 million in 2024, then crashed by 149.16% to -$7.0 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$7.0 million, -$5.4 million, and -$5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.